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ABSTRACT
Introduction: Irritable bowel syndrome (IBS) affects
10–22% of the UK population, with England’s annual
National Health Service (NHS) costs amounting to
more than £200 million. Abdominal pain, bloating and
altered bowel habit affect quality of life, social
functioning and time off work. Current treatment relies
on a positive diagnosis, reassurance, lifestyle advice
and drug therapies, but many people suffer ongoing
symptoms. Cognitive behaviour therapy (CBT) and
self-management can be helpful, but availability is
limited.
Methods and analysis: To determine the clinical-
and cost-effectiveness of therapist delivered cognitive
behavioural therapy (TCBT) and web-based CBT self-
management (WBCBT) in IBS, 495 participants with
refractory IBS will be randomised to TCBT plus
treatment as usual (TAU); WBCBT plus TAU; or TAU
alone. The two CBT programmes have similar content.
However, TCBT consists of six, 60 min telephone CBT
sessions with a therapist over 9 weeks, at home, and
two ‘booster’ 1 hour follow-up phone calls at 4 and
8 months (8 h therapist contact time). WBCBT
consists of access to a previously developed and
piloted WBCBT management programme (Regul8) and
three 30 min therapist telephone sessions over
9 weeks, at home, and two ‘booster’ 30 min follow-up
phone calls at 4 and 8 months (2½ h therapist contact
time). Clinical effectiveness will be assessed by
examining the difference between arms in the IBS
Symptom Severity Score (IBS SSS) and Work and
Social Adjustment Scale (WASAS) at 12 months from
randomisation. Cost-effectiveness will combine
measures of resource use with the IBS SSS at
12 months and quality-adjusted life years.
Ethics and dissemination: This trial has full ethical
approval. It will be disseminated via peer reviewed
publications and conference presentations. The results
will enable clinicians, patients and health service
Strengths and limitations of this study
▪ To date, Assessing Cognitive behavioural Therapy
in Irritable Bowel (ACTIB), when completed, will
be the largest trial, worldwide, to address the
clinical-effectiveness and cost-effectiveness of
cognitive behaviour therapy (CBT) for irritable
bowel syndrome (IBS) and has the advantage of
comparing a low intensity web-based CBT
(WBCBT) with a higher intensity telephone ther-
apist delivered CBT (TCBT).
▪ ACTIB will recruit from both primary and second-
ary care, inviting a broad range of patients with
refractory IBS from specialist as well as commu-
nity settings. This will aid generalisability of the
findings.
▪ Owing to the online nature of the Low intensity
CBT arm, patients without internet access will be
unable to participate. However, internet access in
the UK is currently over 75% and those without
home access could use public computers
(eg, local library).
▪ Participants aged over 60 years must have had a
consultant review to exclude other serious causes
of their bowel symptoms in the past 2 years,
because colorectal cancer is more common in
those over 60 years of age and guidelines recom-
mend that changes in bowel habit in this group
require hospital tests beyond the scope of this trial.
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planners to make informed decisions regarding the management of
IBS with CBT.
Trial registration number: ISRCTN44427879.
INTRODUCTION
IBS is a common chronic gastrointestinal disorder that
affects 10–22% of the UK population and costs the
National Health Service (NHS) in England over 200
million pounds a year.1 2 Abdominal pain, bloating and
altered bowel habit affect quality of life, social functioning
and time off work.3 4 Treatment commonly relies on a
positive diagnosis, reassurance, lifestyle advice and drug
therapies. However, the evidence base for commonly used
medications such as bulking agents and antispasmodics is
limited,4 and many patients suffer ongoing symptoms.
Face to face cognitive behavioural therapy (CBT) has
been shown to be helpful for IBS, reducing IBS
symptom severity and improving QOL measures,5–7 and
it has the potential to have long-term beneﬁts, whereas
medications are aimed at symptom relief. However, CBT
is not currently routinely offered to patients with IBS
due to poor availability. Additionally, face to face CBT in
this setting was not shown to be cost effective in a
Cochrane review5 and there are problems with limited
concordance5 with face to face therapy. For instance, in
the Kennedy trial,6 fewer than half of the participants
were considered to have completed therapy by the end
of the intervention and 41% were recorded as declining
therapy or dropping out, often due to time issues such
as work and child care commitments. Nevertheless,
National Institute for Health and Care Excellence
(NICE) guidance4 recommends CBT for patients with
refractory IBS symptoms (ie, ongoing symptoms after
12 months despite being offered appropriate medica-
tions and lifestyle advice).
A potential approach is to consider web-based CBT
for IBS. Web-based CBT has been shown to be helpful
for a number of long-term conditions, for example,
depression,8 tinnitus9 and fatigue in multiple sclerosis,10
and is recommended in Guidelines for the management
of depression.11 It could be a cost-effective way of provid-
ing help to those with IBS. Recent small pilot trials show
promise for web-based CBT in IBS,12–14 but indicate that
some therapist input is needed. Web-based delivery has
the advantage that it can be accessed at a time and place
convenient to the participant, can be undertaken at a
pace that suits each individual’s circumstances, and does
not require extra travel time and costs. The increasing
availability of the Internet makes this a good medium to
provide easily accessible patient information and self-
management programmes. The majority of households
in the UK now have web access. This is, therefore, an
ideal time to assess and disseminate new web-based
interventions. Members of this team have already devel-
oped a CBT website to support patients with IBS
(Regul8) and trialled it among 135 patients with more
than 90% follow-up in the National Institute of Health
Research (NIHR)-funded MIBS study.14 Even with this
(underpowered) sample, and very minimal nurse input,
Subjects Global Assessment of Relief (SGA) scores
(ie, relief from IBS symptoms) and their Enablement
Scores (sense of control over their IBS) were signiﬁ-
cantly improved in the Regul8 groups compared to the
non-website group at 3-month follow-up.
This trial comparing the clinical-effectiveness and cost-
effectiveness of therapist delivered CBT (TCBT) and a
lower intensity therapist supported web-based self-
management programme will provide evidence to
enable clinicians, patients and health service planners to
make informed decisions regarding the management of
IBS with CBT.
MAIN RESEARCH QUESTION
What is the clinical-effectiveness and cost-effectiveness of
TCBT and web-based CBT (WBCBT) for patients with
refractory irritable bowel syndrome?
RESEARCH OBJECTIVES
Primary objectives
1. Estimate the clinical effectiveness of therapist deliv-
ered telephone CBT (TCBT) plus treatment as usual
(TAU) for reducing the severity and impact of IBS
symptoms compared to TAU alone at 12 months
after randomisation.
2. Estimate the clinical effectiveness of Regul8, a previously
developed web based CBT programme, with minimal
therapist support (WBCBT) plus TAU for reducing the
severity and impact of IBS symptoms compared to TAU
alone at 12 months after randomisation.
Secondary objectives
3. To compare the cost-effectiveness of TCBT and
WBCBT in comparison to TAU over the 12-month
follow-up period.
4. To estimate (1) and (2) at 3 and 6 months after
randomisation.
5. To assess whether TCBT and/or WBCBT have a posi-
tive impact on relief of IBS symptoms, quality of life,
enablement, anxiety and depression compared to
TAU at 3, 6 and 12 months follow-up, and acceptabil-
ity of the treatment.
Tertiary aims
6. To investigate possible cognitive and behavioural
mediators or processes of clinical improvement for
both the TCBT and WBCBT.
7. To examine predictors and moderators of outcome.
METHODS AND ANALYSIS
Design
Three arm multicentre randomised controlled trial.
Method
Four hundred and ninety-ﬁve patients with refractory
IBS will be individually randomised to TCBT+TAU, or
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WBCBT (a previously developed self-management CBT
website with low levels of therapist support)+TAU, or
TAU alone for 9 weeks with 12-month follow-up.
Setting
Treatment will take place at participants’ homes via tele-
phone and internet. Therapists will be based at the
South London and Maudsley NHS Foundation Trust
(SLAM). Participants will be recruited from London and
the South Coast of England from primary and secondary
care.
Target population
Inclusion Criteria: Adults (18 years and over) with refrac-
tory IBS. Refractory IBS is deﬁned for this study as fulﬁll-
ing the ROME III criteria for IBS15 and reporting
ongoing clinically signiﬁcant symptoms determined by a
IBS symptom severity score (IBS-SSS) of 75 or more.
Patients need to have been offered ﬁrst-line therapies
(eg, antispasmodics, antidepressants or ﬁbre based medi-
cations) and have continuing IBS symptoms for
12 months or more. Potential participants aged over
60 years will only be included if they have had a consult-
ant review in the previous 2 years to conﬁrm that their
symptoms are related to IBS and that other serious bowel
conditions have been excluded. This is because there is
an increased risk of bowel cancer in the over 60 years’
age group and clinical guidance suggests further investi-
gations should be undertaken in this group.4
Exclusion criteria: Unexplained rectal bleeding or
weight loss, diagnosis of inﬂammatory bowel disease,
coeliac disease, peptic ulcer disease or colorectal carcin-
oma. People unable to participate in CBT due to speech
or language difﬁculties or those with no access to an
internet computer to be able to undertake the WBCBT
or who have received CBT for IBS in the past 2 years,
and those who have had previous access to the Regul8
website or who are currently participating in an IBS/
intervention trial.
Withdrawal criteria: Participants will be withdrawn from
the trial if there are any concerns regarding informed
consent. Participants can also withdraw if they choose,
without giving a reason. If a participant withdraws
consent for research follow-up during the trial, the trial
team will be informed. Information will be collected in
the Drop-out Report Form and, where possible, reason
for drop out will be recorded.
Planned interventions
Two methods of delivering CBT are being assessed in
this study: TCBT and a lower intensity WBCBT—the
Regul8 website with some therapist support.
There are three key differences between the therapy
trial arms
1. The use of a CBT self-management patient manual
in the TCBT arm versus access to Regul8, an inter-
active, tailored CBT self-management website14 for
the WBCBT arm.
2. The amount of therapist contact time/intensity of
the intervention—TCBT participants will receive a
total of 8 h of telephone therapy contact time com-
pared to 2.5 h in WBCBT.
3. The TCBT telephone sessions will be formulation
driven and, although based on the content of the ses-
sions/chapters of the patient manual detailed below,
order and extent to which these are covered will be
individualised. For WBCBT, patients are encouraged
to work sequentially through the Regul8 sessions,
although the therapist may suggest they focus more
on some sessions than on others.
The CBT content of the two treatments is the same
and is based on an empirical cognitive behavioural
model of IBS.16 The model speciﬁes that factors such as
stress and/or gastric infection trigger the symptoms of
IBS, which are then maintained by patients’ cognitive,
behavioural and emotional responses to the symptoms.
For instance, if a patient becomes anxious (emotion)
about the symptoms, believes he/she has no control
over them (cognitions) and responds by avoiding social
situations (behaviour), this can increase anxiety and
maintain symptoms through the link between a heigh-
tened autonomic nervous system and the enteric
nervous system. This model was used to structure the
content of the therapy sessions in our Regul8 website for
the MIBS pilot study,14 which, in turn, drew from two
efﬁcacious IBS RCTs conducted by members of our
research team, a nurse-delivered CBT trial6 and a trial of
a more minimal CBT based self-management pro-
gramme.16 The therapy consists of education, behav-
ioural and cognitive techniques, aimed at improving
bowel habits, developing stable, healthy eating patterns,
addressing unhelpful thoughts, managing stress,
reducing symptom focusing and preventing relapse.
A summary of the sessions and related homework tasks
are presented in table 1.
Participants randomised to TCBT will be contacted by
one of the therapist teams to organise the therapist tele-
phone sessions, and will be sent a detailed CBT manual
including homework sessions to support the sessions.
The TCBT arm will have six 1 h telephone sessions with
a CBT therapist over 9 weeks as well as homework tasks.
They will also receive two 1 h booster sessions at 4 and
8 months. CBT will be delivered by telephone rather
than face to face, as both have similar efﬁcacy,17 improve
accessibility, are efﬁcient and less costly, and can be
readily delivered from specialist-centralised services
across a large geographic area.17–19
Participants randomised to the WBCBT arm will be
provided with log-in access to Regul8. They will be
advised to start working through the eight online weekly
sessions and homework tasks, and will receive weekly
automated email reminders. In addition, they will
receive three brief 30 min telephone therapy support
calls over 9 weeks and two 30 min booster sessions at
4 and 8 months. The telephone CBT sessions for the
WBCBT arm are undertaken while they are working
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through the website self-management programme to
help engagement with the CBT programme.
Participants will also be able to email the therapist
regarding queries about the website programme, during
the study. Limited therapist input has been included in
this condition as several small trials of web-based12 13 or
manual-based16 CBT for IBS have shown promising
results but indicated that therapist input is important to
maintain participant engagement. Qualitative interviews
with participants from the MIBS20 study also highlighted
the beneﬁt of the telephone support session in improv-
ing patient understanding of Regul8.
Table 1 Summary of the Self-Management Sessions included in the Regul8 website and the TCBT patient manual
Session 1: Understanding your IBS Rationale for self-management, which includes the following explanations
1. Possible causes of IBS and illustrative physiology of the digestive system
together with the functional changes that occur in the gut as a result of
IBS
2. How the autonomic nervous system (‘fight-or-flight’ stress system) may
interact with the enteric nervous system
Session 2: Assessing your symptoms Self-assessment of the interaction between thoughts, feeling and
behaviours, and how these can impact on stress levels and gut symptoms
Development of a personal model of IBS that incorporates these elements
Homework: Daily diaries of the severity and experience of IBS symptoms,
in conjunction with stress levels and eating routines/behaviours
Session 3: Managing symptoms and eating Review of the symptom diary
Behavioural management of the symptoms of diarrhoea and constipation,
and common myths in this area, are discussed. Goal setting is explained
The importance of healthy, regular eating and not being overly focused on
elimination is covered
Homework: Goal setting for managing symptoms and regular/healthy
eating. Goal setting, monitoring and evaluation continue weekly throughout
the programme
Session 4: Exercise and activity Importance of exercise in symptom management is covered
Identifying activity patterns such as resting too much in response to
symptoms or an all-or-nothing style of activity is addressed.
Homework: Goal setting for regular exercise and managing unhelpful
activity patterns if relevant
Session 5: Identifying your thought patterns Identifying unhelpful thought (negative automatic thoughts) in relation to
high personal expectations and IBS symptoms is introduced
Link between these thoughts, feelings, behaviours and symptoms is
reinforced
Homework: Goal setting plus daily thought records of unhelpful thoughts
related to personal expectations and patterns of over activity
Session 6: Alternative thoughts The steps for coming up with alternatives to unhelpful thoughts are covered
together with personal examples
Homework: Goal setting plus daily thought records including coming up
with realistic alternative thoughts
Session 7: Learning to relax, improving sleep,
managing stress and emotions
Basic stress management and sleep hygiene are discussed
Diaphragmatic breathing, progressive muscle relaxation and guided
imagery relaxation, are presented in video and audio formats
Identifying common positive and negative emotions, and the participant’s
current ways of dealing with these
New strategies to facilitate expression of emotion as well as coping with
negative or difficult emotions are discussed
Homework: Goal setting for stress management, good sleep habits and
emotional processing
Session 8: Managing flare-ups and the future The probability of flare-ups is discussed and patients are encouraged to
develop achievable, long-term goals, and to continue to employ the skills
they have learnt throughout the manual to manage flare-ups and ongoing
symptoms
IBS, Irritable bowel syndrome; TCBT, therapist delivered cognitive behavioural therapy.
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In both therapy arms, medical questions will not be
addressed by the therapists, and participants will be
advised to seek medical advice if they have medical
queries. Booster sessions are included in both arms to
discuss any setbacks and to reinforce positive symptom
management.
Secure website pass-wording will ensure non-
contamination of treatments. Patients in the TCBT arm
will also be requested not to share their manual with
others.
Therapists
CBT trained therapists (clinical psychologists or cognitive
behavioural nurse therapists) will provide the telephone
CBT sessions for the TCBT as well as the WBCBT arms of
the study. Each therapist will receive training in both
therapy protocols. Competency ratings will be assessed
for the ﬁrst two patients in each active treatment arm
using a modiﬁed version of the developed rating scale
that had previously been used for assessing competency
in delivering CBT for fatigue in primary care.21
Therapy manuals
A therapy manual has been written and will be used as
the basis to train the therapists. It consists of: informa-
tion and procedures about the trial, background infor-
mation about IBS, a description of the anatomy and
physiology of the bowel, a cognitive behavioural model
of IBS, aspects of the therapeutic alliance, sections on
ways of engaging the patient and on various cognitive,
behavioural and emotional strategies, information on
how to utilise supervision and how to overcome difﬁcul-
ties in the treatment process, and a description of the
two different approaches, TCBT and WBCBT. The
manual also includes protocols for the ﬁve telephone
support sessions for the Regul8 website, including
instructions for the optimum setting for the telephone
calls, in other words, a quiet environment without inter-
ruptions and keeping prompt-sheets handy for the ses-
sions so that the therapist can check that all the key
points are covered.
Therapy training
Therapists will receive two days of training. Prior to the
training days, they will be asked to explore the Regul8
website and read the patient manual. Training consists
of information about IBS including diagnosis, aetiology
and evidence based practice. The IBS CBT treatment
model is presented alongside explanations of how the
bowel works and how this relates to functional distur-
bances such as changes in motility and sensitivity in the
gut in IBS. Therapists are taught to include predispos-
ing, precipitating and perpetuating factors in their
assessment and to use these in a shared conceptualisa-
tion with the patient. Obstacles to engagement and strat-
egies for dealing with these are discussed. The speciﬁcs
of each of the sessions in table 1 are then covered.
Finally, therapists receive an overview of trial protocol
including recording the timing and length of sessions,
any deviations from protocol including sessions missed
or drop out, and conﬁdential storage of
audiorecordings.
Therapy supervision
Post-training, therapists will receive monthly 1.5 h group
supervision with TC, who covers the TCBT, and RMM,
who covers the WBCBT. TC and RMM listen to one
audiorecording from each therapist, and rate these
recordings using the therapist rating scale, prior to
supervision.21 These sessions will be discussed with the
group in supervision. Therapists will also have the
opportunity to discuss any problem areas or challenging
patients. Regular supervision will ensure that the thera-
pists adhere to the protocols in each arm and that the
quality of the therapy is maintained.
Treatment fidelity
All telephone therapy sessions will be audiorecorded for
the purpose of assessing treatment ﬁdelity. These record-
ings will be used for supervision during the study and to
check ﬁdelity throughout the trial. Supervisers will listen
to one TCBT and one WBCBT tape per therapist per
month. A subset of the audiorecordings will be analysed
by two independent clinicians once the trial has ended.
At least two sessions for every therapist (when available)
and for therapy type will be rated in terms of adherence
to the manual or web-based approach (5 item, 7-point
Likert scale). The therapeutic alliance between therapist
and participant will also be rated on a seven-point Likert
scale used in a previous large RCT of treatments for
chronic fatigue syndrome.22
Treatment as usual
Patients in all three arms will receive TAU, with the
control arm being TAU alone. TAU is deﬁned as con-
tinuation of current medications, and usual general
practitioner (GP) or consultant follow-up with no psy-
chological therapy for IBS. All GPs or consultants
involved in the study will receive a copy of the NICE
Guidance for IBS at the start of the study, to ensure all
clinicians have standard best practice information on
IBS management. They will also receive a Desktop
prompt to remind them of the guidelines and inclusion
criteria. All participants will receive a standard informa-
tion sheet on Lifestyle and Diet in IBS, based on the
NICE guidance. Information will be collected on any
changes in IBS treatments/management during the
study, and numbers of GP and consultant consultations
will be recorded for all three arms.
The TAU-alone participants will have access to the
WBCBT website at the end of the trial follow-up period,
but without the therapist support.
Recruitment
Patients will be recruited from secondary and primary
care.
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We plan to recruit 495 participants over 22 months
(23 randomised/month) from GP surgeries in two
regions (Southampton and London) and Secondary
Care Gastroenterology Clinics in two regions
(Southampton and London (GSTT, King’s College
Hospital)).
Primary care patients will be identiﬁed by searching
GPs’ lists for those with a diagnosis of IBS and by oppor-
tunistic recruitment of patients presenting with symp-
toms consistent with IBS. We will utilise the Clinical
Research Network (CRN) to aid recruitment and reten-
tion of GP practices. We will include practices with
urban and rural settings, and with a range of sociodemo-
graphic characteristics. GP practices willing to partici-
pate in the study will search their list for adult patients
aged 18 years and above with a diagnosis of IBS.
Potential participants will be contacted by letter (sent by
the GP surgery) informing them about the trial and
inviting them to take part. The GPs will check the lists
of patients to be contacted prior to the invite letters
being sent out to ensure that it is appropriate to contact
them. The mailing will include the Assessing Cognitive
behavioural Therapy in Irritable Bowel (ACTIB) patient
information sheet. Participants who are interested in
participating in the study will return a reply slip with
their contact details in a prepaid response envelope to
the research team. GPs will also be able to opportunistic-
ally provide information about the trial to potential
recruits during their GP surgeries. Thus, if a patient
with IBS attends a GP consultation, GPs will give them
the patient information sheet regarding the trial, and
the reply slip and envelope. Invite letters will be sent out
from the identiﬁed GP practices in a stepwise manner
over time, and response rates will be monitored to
ensure adequate recruitment levels and a steady work-
load for the therapists.
Secondary care patients will be identiﬁed from gastro-
enterology (GI) clinics. Where available, clinic lists will
be searched for patients with a diagnosis of IBS.
Potential participants will be contacted by letter (sent
from the clinic) informing them about the trial and
inviting them to take part. The Consultants will check
the lists of patients to be contacted prior to the invite
letters being sent out to ensure that it is appropriate to
contact them. The mailing will be as for the primary
care patients. The consultants will also be able to oppor-
tunistically provide information about the trial to poten-
tial recruits during their clinics.
Adverts will also be placed in relevant GP and GI
clinics and on NHS websites. Clinics and GP practices
will have information packs to hand out to potential
participants.
Study procedures
Information is also in the Consort diagram (ﬁgure 1)
and table 2 (screening and data collection).
Those responding to the recruitment invitation letter
will be contacted by the study team to complete a
screening process consisting of the Rome III criteria, and
questions about exclusion and inclusion criteria to check
if they fulﬁl the eligibility criteria for the study. They will
be identiﬁed with a unique ID number. Any patient indi-
cating they may have a ‘red ﬂag’ symptom that would indi-
cate the need for further investigations (ie, unexplained
weight loss or rectal bleeding) will be referred back to
their GP for further assessment and will not enter the
study unless the GP feels the symptoms have been fully
assessed and that the patient is suitable for study entry.
Those fulﬁlling the screening entry requirements will
be contacted by one of the research team to make sure
they are fully informed of trial procedures, and they will
be sent the login and access details for the website in
order for them to complete an on-line consent form.
They will then be sent arrangement details to have a
blood test for full blood count, tissue transglutaminase
antibodies and C reactive protein (CRP), to exclude alter-
native diagnoses, such as anaemia that requires further
investigation and coeliacs disease (as recommended for
IBS diagnosis in the NICE guidelines4). The blood tests
will be undertaken by practice nurses/GPs within the GP
surgeries or by phlebotomists/research nurses at the sec-
ondary care sites. Samples will be sent to University
Southampton Hospital pathology laboratory for testing
and will then be destroyed. The results will be made avail-
able to the participants’ GP. If the blood tests are within
normal limits, the participant can complete the baseline
measures and can then be randomised. If the blood tests
show an abnormal result, that is, a CRP over the normal
laboratory range, anaemia or a positive test for coeliacs
disease, the patient will not be randomised to the trial
but will be referred back to his or her GP for further
assessment.
Randomisation
Randomisation will be provided by an independent ran-
domisation service at the UKCRC registered King’s
Clinical Trials Unit (CTU) and accessed by study sites via
a web-based system. Randomisation will be at the level of
the individual, using block randomisation with randomly
varying block sizes, stratiﬁed by centre (Southampton
GP practices, Southampton secondary care, London
GP practices, London secondary care). Conﬁrmation
emails will be generated automatically and sent to rele-
vant study site and coordination staff.
Blinding
It is not possible in therapy trials to blind participants or
therapists to treatment allocation, however, no hypoth-
eses have been proposed as to the superiority of one
treatment over the other. As the research assistants are
responsible for allocating patients to therapists who have
current availability, they will also be unblinded, however,
the principal investigators and statisticians will remain
blinded. All outcomes are patient reported and col-
lected via the internet, following automated email
reminders. The trial team member who will contact
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participants to capture primary outcome data by tele-
phone on the short questionnaire for those who have
not completed follow-up questionnaires after email
reminders, will be blinded to the participants treatment
group, to avoid bias.
Locked codes will be used for treatment allocation
and the trial statisticians will be blinded to treatment
allocation, as will be the Data Monitoring and Ethics
Committee (DMEC), in order to take actions on the
basis of the unblinded data alone. The majority of the
data will be analysed blind and the codes only unlocked
when necessary, to enable analysis of therapist effects.
Data collection
Research data will be entered onto GCP compliant
online data entry systems at CTU (InferMed MACRO)
and Regul8 on the LifeGuide Platform. Invite reply data
will be entered into the Research Team databases locally.
Participant screening data will be collected by telephone
and entered into MACRO by the study site staff. Baseline
data will be collected prior to randomisation. Baseline
and outcome data will be patient self-completed on a
separate data collection section of the Regul8 website
(as was carried out successfully for the MIBS study),
away from the study team, thus avoiding any inﬂuence
Figure 1 Consort diagram for
Assessing Cognitive behavioural
Therapy in Irritable Bowel
(ACTIB).
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of the study team on the responses and reducing bias.
This website will be maintained by the computer
support team at Southampton, which is hosting the
website. Participants will be given a unique password to
log onto the website. Their data will be identiﬁed by a
unique identiﬁcation number and will be kept separate
from any personal identifying data, to maintain conﬁ-
dentiality. A Therapist database on the CTU MACRO
system will be completed by the therapists. It will record
which therapist provided the sessions, number of ses-
sions and other contact telephone calls, any drop outs
from therapy and a therapist-recorded rating of patient
change, adherence and acceptance of therapy model.
Baseline measures
The screening questionnaire will capture baseline data
including Rome III questionnaire, duration of IBS, type,
previous CBT, medications previously taken for IBS, and
inclusion and exclusion criteria. The participant will
complete an online baseline assessment questionnaire,
which includes the outcome measures detailed below
plus sociodemographic details, current medication,
medical history and medications, duration of IBS symp-
toms and previous or current psychiatric diagnoses.
Outcome measures
Outcome data and questionnaires will be completed at
baseline, 3, 6 and 12 months after randomisation, by all
participants. Participants will be sent a reminder email
at 3, 6 and 12 months, to prompt them to complete
entering the data 1 week prior to the questionnaire due
date. If it has not been completed within 1 week of the
reminder, a further two reminders will be sent. One
week after that, if no data have been entered, the
research team will ring the participant to ask if they can
collect the data by hard copy or over the telephone.
90% follow-up was achieved (at 12 weeks) by this
method in the MIBS trial, which collected very similar
Table 2 Screening and data collection across the trial: summary of the key trial processes from receipt of the invite reply
from the potential participant to the data collection time points
CRF
Completed
by Database Preconsent Baseline 3 m 6 m 12 m
Ongoing
or during
treatment Ref
Invite reply P RT X na
Screening Questionnaire P/TT M X na
Consent P R X na
Sample requisition form RN RT X na
Adverse events form TT M X na
Drop-out event form TT M X na
Note review form TT M X na
IBS-SSS P R X X X X 23
WASAS P R X X X X 24
SGA P R X X X 25
EQ5D P R X X X X 26
Patient enablement P R X X X 27
Hospital Anxiety and Depression
Scale
P R X X X X 28
Client Service Receipt Inventory P R X X X X 29
Cognitive Scale CG-FBD P R X X X X 30
B-IPQ for IBS P R X X X X 31
IBS Behavioural Responses
Questionnaire
P R X X X X 32
BES P R X X X X 33
“Impoverished Emotional
Experience (IEE)” factor of the
Emotional Processing Scale-25
P R X X X X 34
PANAS P R X X X X 35
Demographics P R X na
About your IBS P R X na
Safety questions P R X X X na
Rating of satisfaction P R X X X 22
Thoughts on my treatment P R X X X 36
Therapist database T MT X na
BES, Beliefs about Emotions Scale; B-IPQ, Brief Illness Perception Questionnaire; CG-FBD, Cognitive Scale for Functional Bowel Disoders;
CRF, Case Report Form; IBS, Irritable bowel syndrome; IBS-SSS, IBS Symptom Severity Score; M, MACRO Clinical Trials Unit database;
MT, MACRO Therapist database; na, not significant; P, patient; PANAS, Positive and Negative Affect Schedule; SGA, Subject’s Global
Assessment of Relief; R, LifeGuide Regul8; RN, Research Nurse/Phlebotomist; RT, Research Team database; T, therapist; TT, trial team;
WASAS, Work & Social Adjustment Scale.
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baseline and outcome measures to those proposed for
this study.
Primary outcomes: IBS-SSS and WASAS
IBS Symptom Severity Score (IBS SSS)23 is widely used
in IBS studies. It is a ﬁve item self-administered question-
naire measuring: severity of abdominal pain, duration of
abdominal pain, abdominal distension/tightness, bowel
habit and quality of life. (Maximum score 500: <75
normal bowel function, 75–174 mild IBS, 175–299 mod-
erate IBS, 300–500 severe IBS). A 50 point change from
baseline is regarded as clinically signiﬁcant.23
The Work and Social Adjustment Scale (WASAS) mea-
sures the effect of the IBS on people’s ability to work
and manage at home, participate in social and private
leisure activities, and maintain relationships.24 WASAS
has been shown to be sensitive to change in IBS trials.6 16
It has ﬁve aspects scored 0 (not affected) to eight
(severely affected), total possible score 40.
Secondary outcome measures
Two of the secondary outcomes will not be completed at
baseline, only at follow-ups These include the SGA
(Subject’s Global Assessment of Relief)25 and the
Patient Enablement Questionnaire.16
The SGA is frequently used in treatment trials to iden-
tify IBS responders to therapy.25 Participants rate their
relief from IBS symptoms on a scale of 1–5 ranging from
‘completely relieved’ to ‘worse’. Scores are dichotomised
so that patients scoring from 1 to 3 are considered
responders and those scoring 4–5, non-responders.
The Patient Enablement Questionnaire27 assesses
change in the participants’ ability to cope with their
illness and life after treatment.
Mood will be measured by the Hospital Anxiety and
Depression Scale (HADS),28 a well validated, commonly
used, self-report instrument for detecting depression
and anxiety in patients with medical illnesses.
The acceptability of the self-management treatment
will be assessed using questions where patients rate the
overall effectiveness of the programme, the efﬁcacy of
programme compared to other treatments they have
tried and whether they enjoyed the programme.
The Client Service Receipt Inventory (CSRI)29 and
EQ-5D26 will be used to gather information on use of
health services, and health-related quality of life, respect-
ively. The CSRI has been adapted for use in many eco-
nomic evaluations and has been used in previous IBS
evaluations. The EQ-5D is the most frequently used tool
for generating quality-adjusted life years (QALYs), which
are favoured by NICE.
Adherence to therapy
Patients’ adherence to the treatments will be measured
through recording the number of phone sessions and
an automated count of web sessions accessed.
Completing four or more sessions of the website and
one or more of the telephone support calls will be
deemed as compliant with the website. In the TCBT
arm, completing four or more of the initial telephone
CBT sessions will be deemed as compliant.
Any modiﬁcations or departures from randomised
treatments, and withdrawal of participants from trial
treatment or research follow-up, will be recorded and
reported as such.
Putative mediator variables
Mediator variables include cognitions and behaviours
that form part of the cognitive behavioural treatment
model and are targets of the therapies.
These include
Cognitive Scale for Functional Bowel Disoders
(CG-FBD),30 a 31 item scale assessing unhelpful cogni-
tions related to IBS.
Brief Illness Perception Questionnaire for IBS
(IPQ),31 consisting of an eight point scale to assess parti-
cipants perception of their illness.
The Belief about Emotions Scale (BES),33 a 12-item
questionnaire that measures beliefs about the unaccept-
ability of experiencing and expressing negative emo-
tions. These beliefs are likely to have implications for
emotion regulation and processing.
The Irritable Bowel Syndrome-Behavioural Responses
Questionnaire,32 a 26 item scale that measures changes
in behaviour speciﬁc to managing IBS symptoms.
The “Impoverished Emotional Experience (IEE)”
factor of the Emotional Processing Scale,34 which is com-
posed of ﬁve items, and relates to the labelling and
awareness of emotional events that inﬂuence the way
people process their emotions.
The Positive and Negative Affect Schedule (PANAS),35
which measures both positive and negative affect. The
current results indicate that positive and negative effect
are relatively independent dimensions. Participants will
complete only the positive effect subscale because the
HADS scale will already measure negative effect.
GP notes review
Patients’ GP notes will be reviewed at 12 months to assess
GP and other consultations in the year prior to entering
the study and in the 12 months since entry into the study.
Other studies have shown an impact on GP contacts from
patient self-management programmes.16 37
Qualitative component
A nested qualitative study will explore patients’ experi-
ences of treatments. The objectives of this study are: to
identify factors that facilitate or impede adherence to
web-delivered and therapist-delivered CBT; to provide
insight into the quantitative results; and to explore social
and psychological processes of change. Semistructured
interviews will be conducted at 3 and 12 months, with
approximately 17–20 participants per arm (ie, 10–12%,
sampled purposively to encompass a mix of gender and
ages, and a range of baseline symptom severity scores).
Interviewers will use topic guides comprising open-
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ended questions and prompts designed to elicit partici-
pants’ accounts of their experiences of IBS in relation to
the trial. Interviewing participants from each active arm
will enable us to identify factors related to adherence
and change processes; including participants from the
TAU arm will provide insight into the quantitative
results. Interviewing the same participants at 3 and
12 months will allow us greater depth to explore change
processes over time and provide the potential to under-
stand better any differences in the quantitative results
between 3 and 12 months. Interviews will be transcribed
verbatim. Analysis will begin on completion of the ﬁrst
few interviews and will proceed iteratively, thus allowing
early insights to be explored more fully in later inter-
views and topic guides to be modiﬁed if necessary.
Inductive thematic analysis,38 employing supplementary
techniques from grounded theory,39 will be used to code
the data and to identify themes that capture key con-
cepts and processes. To enhance quality: multiple
researchers will contribute, to avoid producing idiosyn-
cratic interpretations; a ‘member check’ will be con-
ducted whereby interviewees will be invited to comment
on summaries of their interviews; and an audit trail
(coding manual and notes) and interviewers’ ﬁeld notes
will be produced. The qualitative results will thus
provide insights into the relative merits of each type of
CBT and identify delivery issues to attend to in any
future widespread implementation.
Proposed sample size
Sample size was based on the two primary outcomes,
IBS-Symptom severity score (IBS-SSS)23 and WASAS.24 40
A 35 point difference between therapy groups and
TAU on IBS SSS at 12 months is regarded as clinically
signiﬁcant (assuming a 15 point placebo response in the
TAU arm in the trial).23 Assuming a within-group IBS
SSS standard deviation (SD) of 76 points (taken from
MIBS pilot study14), this equates to an effect size of 0.46.
To achieve 90% power to detect such an effect or larger
using a two-sided independent samples t test at the 2.5%
signiﬁcance level (adjusting for 2 primary outcomes),
would require 119 subjects per group. Based on each of
10 therapists delivering therapy to 17 patients within
WBCBT and TCBT groups, and an intraclass correlation
of 0.02, taken from Baldwin,41 this sample size needs to
be increased by an inﬂation factor of 1.32, to take
account of therapist effects. We will measure IBS SSS at
baseline and assume that baseline values are predictive
of post-treatment values (correlation 0.4). Accounting
for this in our statistical analysis model allows us to
decrease the sample size by a deﬂation factor of 0.84.
Finally, assuming that attrition will be less than 20%, we
apply a further inﬂation factor (factor 1.25) to allow for
this. The ﬁnal sample size requirement is 165 patients
per group, or 495 patients in total.
In terms of our second primary outcome (WASAS),
this sample size would be sufﬁcient to detect a clinically
important difference between the WBCBT (or TCBT)
and TAU groups in the WASAS. Speciﬁcally, we can
assume inﬂation factors of 1.32 for correlation of out-
comes within therapists, and of 1.25 for attrition and a
deﬂation factor of 0.84, for correlation between baseline
and follow-up measures. Therefore, a moderate effect
size of 0.46 could be found with 90% power at the 2.5%
signiﬁcance level, given 119 participants per group.
Assuming a SD of 8.0 (as estimated in a study of CBT
for IBS6), this would equate to a clinically meaningful
treatment difference of 3.7 points on this scale. This is
less than the difference of 5.4 points in change of
means that was found in a trial of a CBT-based self-
management intervention for IBS.16
Statistical analysis
The Statistical analysis plan has been approved by the
trial steering committee. The aim is to evaluate effective-
ness, and all analyses will follow the intention-to-treat
principle. Group differences on the primary IBS-SSS
outcome will be assessed using a mixed linear regression
model for repeated measurements. In this model,
IBS-SSS at post-treatment time points (3, 6 and
12 months) will feature as the dependent variable.
Explanatory variables will be baseline IBS-SSS, treatment
group, IBS symptoms type, stratiﬁer (centre) and time
and time by treatment interaction terms to allow for dif-
ferent group differences at the various assessment time
points. (The assessment time point of primary interest is
12 months. The modelling provides the treatment effect
estimates at the 12 month time point as well as for
further post-treatment secondary time points).
Correlation between repeated measures of the same par-
ticipant or between participants, or due to sharing the
same therapist, will be allowed for by including subject-
varying random intercepts as well as therapist-varying
random intercepts for TCBT and WBCBT groups in the
mixed models. Mixed models account for missing
outcome data under the missing at random assumption.
The effect of departures from this assumption will be
checked using sensitivity analyses.42 WASAS scores will
be analysed using mixed models in a manner similar to
the analysis of IBS-SSS. Secondary outcomes, including
Subjects’ Global assessment of relief (SGA), EQ-5D,
Enablement, HADS, Brief Illness perception
Questionnaire (IPQ), Cognitive Scale for Functional
Bowel disorders, The Belief about Emotions Scale
(BES), The “Impoverished Emotional Experience
(IEE)” factor of the Emotional Processing Scale, The
Positive and Negative Affect Schedule (PANAS), adverse
events (AEs) and healthcare utilisation, are important to
measure the wider IBS effects and will be analysed simi-
larly (as appropriate for continuous or dichotomous out-
comes). A complier average causal treatment effect will
be estimated using instrumental variable methods to
assess efﬁcacy if there is appreciable lack of
compliance.43
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Economic evaluation
We will measure costs and assess cost-effectiveness from
both a health service and a societal perspective. To cal-
culate the cost of TCBT, the number of sessions with
therapists will be recorded and combined with the unit
cost of therapist time. The latter will be calculated using
information on the salary band of therapists, with add-
itional costs representing capital, overheads, training
and qualiﬁcations.44 We will ask therapists to estimate
how much time during a typical working week is spent
in telephone contact with patients, and combine this
with the total cost and total hours worked per week, in
order to produce a cost per hour of direct patient contact
time. For WBCBT, the number of times therapist support
is provided will be recorded and costed in a similar way.
The WBCBT development costs will be estimated and
apportioned over those using the intervention. Other
service use will be measured with a service receipt sched-
ule at baseline (going back 6 months) and at each
follow-up (with measurement covering the whole period
since the prior interview). The schedule will be based on
other questionnaires used in similar research.29 Services
will include primary and secondary healthcare, and medi-
cation. Service costs will be generated by combining these
data with appropriate unit cost information (eg, NHS
Reference Costs,44 and the British National Formulary)
and these costs added to the intervention costs in order
to generate total health costs per person.
Societal costs will be calculated by including family
care costs and lost production. Family care costs will be
recorded by asking patients to state how much time per
week family members (and friends) spent providing
support in speciﬁc areas because of the IBS. This time will
be combined with average wage rates. Lost days and
hours from work will be recorded on the schedule and
combined with average wage rates to generate lost pro-
duction costs. Cost comparisons between the three
groups will be made at 3, 6 and 12 months, and over the
entire follow-up period, in both cases, controlling for
baseline costs. Cost data are usually skewed and cost
comparisons will use a bootstrapped regression model to
generate appropriate 95% CIs around the cost
differences.
Cost-effectiveness will be assessed (from health and
societal perspectives) by combining the cost data with
the change score on the IBS-SSS, WASAS and QALYs.
The latter will be generated from the EQ-5D combined
with UK-speciﬁc tariffs. Area under the curve methods,
controlling for baseline utility, will be used to calculate
the number of QALYs accrued over the follow-up
period. If outcomes are better for one group compared
to another and costs are lower, then it will be deﬁned as
being ‘dominant’. If outcomes are better and costs are
higher, an incremental cost-effectiveness ratio will be
generated to indicate the extra cost incurred to achieve
an extra point reduction in symptoms or extra QALY.
Cost-effectiveness planes will be produced, using 1000
cost and outcome differences (from bootstrapped
regression models) for each 2-way comparison, to
explore the uncertainty around the results.
Cost-effectiveness acceptability curves will also be pro-
duced using bootstrapped regression models with net
beneﬁt values as the dependent variables. The net
beneﬁt approach requires an assumption about the
value placed on a unit improvement in outcome. For
QALYs, a range from £0 to £60 000 will be used, thus
including the threshold thought to inﬂuence NICE deci-
sions. For the IBS-SSS and WASAS, there are no
accepted thresholds, so a range will be chosen such that
the points at which one intervention has a 60%, 70%,
80% and 90% likelihood of being the most cost-effective
option can be identiﬁed.
Sensitivity analyses will be conducted by changing the
intervention costs upwards and downwards by 50%,
using minimum wages to value lost production, family
care and travel time, and by also using the replacement
cost approach to value family care with the cost of a
homecare worker used a shadow price.
Modelling beyond the trial period and making com-
parisons with other interventions is not in the scope of
this project.
ETHICS AND DISSEMINATION
Ethical issues
The trial will be conducted in full accordance with
current guidelines for ethical research conduct. The
study will be performed subject to Research Ethics
Committee (REC) approval, including any provisions of
Site Speciﬁc Assessment (SSA), and local Research and
Development (R&D) approval.
The potential beneﬁt to participants from the inter-
ventions in this study is a greater understanding of their
IBS, an improved ability to manage their condition and
possibly reduced symptom severity or impact on their
life from their IBS. This may lead to societal beneﬁts
such as a reduction in work days lost and reduced use of
NHS resources. The risks of undertaking CBT are
minimal; undertaking the sessions will require a time
commitment on behalf of the participants, and focusing
on their IBS symptoms could temporarily worsen the
symptoms in the short term. The CBT is provided along-
side usual care so the participants will still have access to
all usual NHS services. Participants will be fully informed
of the trial procedures before entering the study via a
Patient Information Sheet, and any questions will be
answered by the research team prior to signing the
on-line consent form.
Fair access to the study
Participants need to have web access, which could
exclude some people who would otherwise like to take
part. However, three quarters of households have web
access, this ﬁgure is rapidly increasing, and those
without home access can use public computers (eg,
local library).
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Participants aged over 60 years are required to have
undergone a consultant review to exclude other serious
causes of their bowel symptoms in the last 2 years,
because colorectal cancer is more common in those
aged over 60 years and guidelines recommend that
changes in bowel habit in this group require hospital
tests beyond the scope of this trial.
To maximise recruitment and to ensure that motivated
patients are not excluded from treatments that may
help, participants in the TAU-alone group will be given
access to the Regul8 website at the end of the trial.
Dissemination
The results of this study will be communicated to partici-
pants at study end and disseminated via peer reviewed
publications and conference presentations. The results
will enable clinicians, patients and health service plan-
ners to make informed decisions regarding the manage-
ment of IBS with CBT.
Service users
IBS patients and the IBS network, a patient self-help
group, have been involved in providing feedback for the
design of the MIBS14 trial (in which the Regul8 website
used in this study was developed and piloted). Patients
were substantially involved in the website design with
service users, working through each on-line module
during development and providing ‘Think Aloud’ feed-
back to inform the design. Participants from the MIBS
trial have also provided input and feedback on the pro-
posals for this research. Two participants are now PPI
representatives for this study, providing ongoing input
(both informal feedback and participating in Trial
Steering Committee (TSC) and research meetings) to
ensure it addresses issues relevant to users.
Research governance
This study will be conducted in accordance with the
International Conference for Harmonisation of Good
Clinical Practice (ICH GCP) guidelines, and the
Research Governance Framework for Health and Social
Care. The University of Southampton is the Sponsor for
this study.
A Trial Steering Committee (TSC) will oversee the
trial procedures and ensure good conduct of the study;
they will meet at least annually. Observers from the HTA
will be invited to all TSC meetings.
A Data Monitoring and Ethics Committee (DMEC)
will oversee the trial data and ethics, with an independ-
ent chair and at least two independent members, and a
Patient and Public Involvement Representative, along
with the lead investigator (HE), with the support of the
TSC. They will meet at least annually.
Regular updates and meetings will ensure good com-
munication. The collaborators will hold meetings at least
four times a year. The research assistant will circulate a
monthly update to review progress relative to the project
plan, highlighting any issues that need to be addressed.
Each team member will consult the other team
members immediately by email and/or phone on any
issues that arise.
Monitoring and audit
The study will be monitored and audited in accordance
with Southampton University procedures. All trial
related documents will be made available on request for
monitoring and audit by the University of Southampton,
the relevant REC and other licencing bodies.
Safety
Adverse events
AE are any clinical change, disease or disorder experi-
enced by the participant during their participation in
the trial, whether or not considered related to the use of
treatments being studied in the trial.
Serious adverse events
An AE is deﬁned as serious (an SAE) if it results in one
of the following outcomes
▸ A life-threatening AE
▸ In-patient hospitalisation
▸ A disability/incapacity
▸ A congenital anomaly/birth defect in the offspring of
a subject
▸ Other medical events requiring intervention to
prevent one of the above outcomes.
Serious adverse reactions
A serious adverse reaction (SAR) can be deﬁned as:
A SAE considered to be a reaction to one of the supple-
mentary therapies.
Reporting serious adverse events and reactions
(SAEs and SARs)
On completion of an SAE, the chief investigator will
assess whether the SAE is a SAR or a (SUSAR).
A SUSAR is any adverse reaction that is classed as
serious and is suspected to be caused by the interven-
tion, and is not expected. If the SAE is classiﬁed as a
SUSAR, the trial team will report the SUSAR to the EC.
For a SUSAR that is fatal or life-threatening, the team,
on behalf of the sponsor, has 7 days to report the
SUSAR to the EC. For a SUSAR that is not fatal or life-
threatening, the team has 15 days to report. The SUSAR
is recorded in the participant’s medical notes and the
participant will be followed up.
Follow-up after AEs
After a SAE or SAR, a decision will be made by the trial
team, after advice from the relevant authorities and the
participant’s GP, as to whether the participant should be
withdrawn from either their randomised treatment or
from the trial. Arrangements will be made by the trial
team for further assessment and management as agreed
with the relevant authorities, GP and participant. The
investigator will provide the trial team with a 1-month
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follow-up report on all SAEs and SARs. Further monthly
reports should be provided in the absence of resolution.
These reports will be communicated to the TSC, DMEC
and MREC, and to the local R&D ofﬁce. Blank Adverse
Event Forms will be distributed to sites that are recruit-
ing, and therapists and patients will be prompted to self-
report SAEs in the follow-up questionnaires.
AEs that do not require reporting
Expected AEs include planned/elective hospitalisations,
and these will not be collected as SAEs.
Stopping rules
The trial may be prematurely discontinued by the
Sponsor or Chief Investigator on the basis of new safety
information or for other reasons given by the Data
Monitoring & EC, Trial Steering Committee, Regulatory
Authority or EC concerned.
The trial may also be prematurely discontinued due to
lack of recruitment or on advice from a Trial Steering
Committee (if applicable), who will advise on whether
to continue or discontinue the study and make a recom-
mendation to the sponsor. If the study is prematurely
discontinued, active participants will be informed and
no further participant data will be collected.
Data protection and anonymity
Data will be collected and retained in accordance with
the Data Protection Act 1998.
The Data Protection policy of the School of Medicine,
Southampton University, will be complied with.
GP participants will be identiﬁed from Health
Authority lists (these are available in the public domain)
and via the CRN.
The responses to questionnaires will be stored in an
anonymised form on a password protected university or
CTU server. Any anonymised paper questionnaires will be
stored in a locked ﬁling cabinet at Primary Medical Care—
University of Southampton, or at King’s College London.
Storage of records
Study documents (paper and electronic) will be
retained in a secure location during and after the trial
has ﬁnished. All source documents will be retained for a
period of 10 years following the end of the study.
CONCLUSION
This paper outlines the protocol for the ACTIB study.
This study has signiﬁcant strengths: to date, ACTIB, when
completed, will be the largest trial worldwide to address
the clinical-effectiveness and cost-effectiveness of CBT for
IBS and has the advantage of comparing a low intensity
web-based CBT (WBCBT) with a higher intensity tele-
phone delivered CBT (TCBT). Additionally, ACTIB will
recruit from both primary and secondary care, inviting a
broad range of patients with refractory IBS from specialist
as well as community settings. This will aid generalisability
of the ﬁndings.
The limitations of this study are that due to the online
nature of the Low intensity CBT arm, patients without
internet access will be unable to participate. However,
internet access in the UK is currently over 75% and
those without home access can use public computers
(eg, local library). Also, participants aged over 60 years
are required to have undergone a consultant review to
exclude other serious causes of their bowel symptoms in
the past 2 years, because colorectal cancer is more
common in the those aged over 60 years, and guidelines
recommend that changes in bowel habit in this group
require hospital tests beyond the scope of this trial.
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